Bibliographic record
Abstract
In 1971, the pharmaceutical producer's affiliated participants spent approximately $360 million on R&D. In 1991, they spent $8.9 billion, an increase of over 2300 percent. Although industry income has grown in step with research expenditures, there has been no full-size increase within the range of the latest tablets introduced. Why have the costs increased dramatically? Breakthroughs in pharmaceutical research can lay the foundation for qualitative improvements in the quality of existence and large discounts on the price of healthcare. However, escalating healthcare fees have focused on each factor of healthcare expenditure, which has led several observers to question the apparent decline in the productiveness of pharmaceutical studies. This bankruptcy hopes to contribute to the controversy by exploring the issue in the context of a broader examination of the determinants of study productivity in the discovery of ethical drugs. We draw upon detailed facts compiled from the internal records of the ten most important pharmaceutical companies. The statistics set allows us to distinguish between studies (or discoveries) and improvement expenses at an enormous dis aggregated stage. For instance, in the standard magnification of cardiovascular cures, we can observe distinctions among fields such as hypertension, cardio tonic, and blood-associated conditions. This study presents several descriptive facts from the sample. Our pattern corporations show a long-term decline in productivity, which is a feature of the industry as a whole. Each study and development expenditure has improved dramatically in actual terms, even as the output of important patents has fallen and the wide variety of capsules observed has remained approximately the same.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.046 | 0.255 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.007 | 0.007 |
| Science and technology studies | 0.003 | 0.007 |
| Scholarly communication | 0.006 | 0.003 |
| Open science | 0.002 | 0.006 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".